Umbilical cord blood treats children born with non-cancerous genetic disorders

Researchers at UPMC Children's Hospital of Pittsburgh found that infusing umbilical cord blood -- a readily available source of stem cells -- safely and effectively treated 44 children born with various non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD) and an array of immune deficiencies. This is the largest trial of its kind to date.

The idea was to create a fairly universal treatment, rather than chasing individual therapies for all of these rare diseases, and to do so with minimal risk to the patients. The results were published in today's print edition of Blood Advances.

"There has been a lot of emphasis placed on cool new technologies that might address these diseases, but -- even if they prove effective -- those aren't available to most centers," said study senior author Paul Szabolcs, M.D., division director of bone marrow transplantation and cellular therapies at UPMC Children's Hospital. "The regimen we developed is more robust, readily applicable and will remain significantly less expensive."

For this study, the participants received intravenous injections of banked cord blood, which was donated from the umbilical cords and placentas of healthy babies just after birth and frozen until needed.

To make room in their bone marrow for donor stem cells to take root and prevent them from being rejected, study participants received a low dose of chemotherapy and immunosuppressant drugs in a careful sequence. Once the cells integrated into the patients' bodies, these drugs were tapered off.

To kick the immune system back into gear, the researchers reserved a small fraction of the cord blood and gave it to participants a few weeks after the initial infusion.

It's important to note that this procedure doesn't require the donor and recipient to have matching immune profiles.

That's huge for ethnic minorities, the probability of a perfect match is very low, but with a cord blood graft, we have a chance to overcome this discrepancy over the course of a couple months and then taper immunosuppressants away."

Paul Szabolcs MD, Study Senior Author and Division Director, Bone Marrow Transplantation and Cellular Therapies, Children Hospital, University of Pittsburgh Medical Center

Overall, post-infusion complications were relatively mild. None of the participants experienced severe chronic graft-versus-host disease, and the mortality rate from viral infection due to immune suppression was 5%, which is much lower than in prior studies.

For the 30 children in the trial with metabolic disorders -- in which improper enzyme function causes the buildup of harmful toxins in the body -- all but one exhibited progressive symptoms of neurodevelopmental delays before the start of the trial.

Within a year of receiving cord blood, all of them had normal enzyme levels, and all showed a halting of neurological decline. Some even began to gain new skills.

The most common metabolic disorders in this study were leukodystrophies, which typically are fatal within a few years of symptom onset.

Even with cord blood treatment, a large retrospective analysis reported a three-year survival rate of about 60%. With the protocol used in this study, more than 90% of symptomatic leukodystrophy patients were still alive three years after their cord blood treatment.

No previous studies using stem cells to treat metabolic, immune or blood disorders have shown such high levels of safety, efficacy or broad applicability.

"There has been a stagnation of outcomes in this field, just changing one chemotherapy agent for another, not a true evolution," Szabolcs said. "We designed an approach now proven to be efficacious for at least 20 diseases. And we believe it might be effective for many, many more."

Since this paper was submitted, the researchers already have had success with using this technique to treat additional diseases, including in adults.

Source:
Journal reference:

Lugt, M. T. V., et al. (2020) Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Advances. doi.org/10.1182/bloodadvances.2020001940

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revealing the Genetic Mechanisms Driving SARS-CoV-2 Variants